CLINICAL TRIALS PROFILE FOR XTANDI

All Clinical Trials for xtandi

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00268476 ↗	Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy	Recruiting	Medical Research Council	Phase 2/Phase 3	2005-07-08	The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer. This trial aims to see if we can improve the way in which prostate cancer is currently managed, either by adding new treatments to the standard approach or by modifying the type of hormone therapy aiming to improve quality-of-life by reducing the side effects of treatment. Each new treatment approach is compared against a control arm receiving the current standard treatments. We aim to identify treatment strategies that enable men to live longer, or as long but with an improved quality-of-life, as well as offering value for money for the health service. Since opening to accrual in Oct-2005, the trial has tested many ways of treating prostate cancer and some results are now already known. More than 10,000 men will join the trial with answers becoming available throughout the trial. New patients joining the trial from Protocol version 17.0 onwards (activated in December 2018) may be eligible to join one of two treatment comparisons, metformin (treatment group K; the "metformin comparison") and transdermal oestradiol (treatment group L; the "transdermal oestradiol comparison"). A computer program will be used to allocate which treatment each participant receives, using a chance process. Summary of the research arms in STAMPEDE trial platform Summary of research treatment groups currently open to recruitment (June 2017) 1. Metformin (Arm K): This anti-diabetic medication is proposed to have both anti-cancer effects and may help prevent the adverse metabolic effects of long-term ADT. STAMPEDE will investigate whether adding metformin to the current standard-of-care for non-diabetic men can improve all-cause survival. 2. Transdermal oestradiol (Arm L): This is an alternative form of hormone treatment which has been shown to suppress testosterone as effectively as standard ADT and avoid some of the side-effects. It may also help to avoid the adverse metabolic effects and fatigue and therefore improve overall quality of life compared with standard forms of ADT. STAMPEDE will investigate whether transdermal oestradiol can treat the cancer as well as current standard forms of ADT. 3. Control group (Arm A): Patients allocated to this group receive the current standard-of-care ADT +/- RT +/- docetaxel.
NCT00510718 ↗	A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer	Completed	Astellas Pharma Inc	Phase 1	2007-07-23	This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.
NCT00510718 ↗	A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer	Completed	Medivation LLC, a wholly owned subsidiary of Pfizer Inc.	Phase 1	2007-07-23	This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.
NCT00510718 ↗	A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer	Completed	Medivation, Inc.	Phase 1	2007-07-23	This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.
NCT00510718 ↗	A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer	Completed	Pfizer	Phase 1	2007-07-23	This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.
NCT00974311 ↗	Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy	Completed	Astellas Pharma Inc	Phase 3	2009-09-30	This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

Clinical Trial Conditions for xtandi

Condition Name

Condition Name for xtandi
Intervention	Trials
Prostate Cancer	47
Castration-Resistant Prostate Carcinoma	13
Stage IV Prostate Cancer	13
Metastatic Castration-Resistant Prostate Cancer	11

Condition MeSH

Condition MeSH for xtandi
Intervention	Trials
Prostatic Neoplasms	135
Carcinoma	20
Adenocarcinoma	18
Prostatic Neoplasms, Castration-Resistant	11

Clinical Trial Locations for xtandi

Trials by Country

Trials by Country for xtandi
Location	Trials
United States	643
United Kingdom	122
Canada	89
France	82
Spain	75

Trials by US State

Trials by US State for xtandi
Location	Trials
California	41
New York	35
Texas	32
Maryland	29
Illinois	28

Clinical Trial Progress for xtandi

Clinical Trial Phase

Clinical Trial Phase for xtandi
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	17
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for xtandi
Clinical Trial Phase	Trials
Completed	46
Recruiting	45
Active, not recruiting	31

Clinical Trial Sponsors for xtandi

Sponsor Name

Sponsor Name for xtandi
Sponsor	Trials
Medivation, Inc.	47
Astellas Pharma Inc	31
National Cancer Institute (NCI)	25

Sponsor Type

Sponsor Type for xtandi
Sponsor	Trials
Industry	197
Other	144
NIH	25

Clinical Trials Update, Market Analysis, and Projection for Xtandi (Enzalutamide)

Last updated: January 13, 2026

Summary

Xtandi (enzalutamide) remains a cornerstone in targeted prostate cancer therapy, particularly for metastatic castration-resistant prostate cancer (mCRPC). As of 2023, ongoing clinical trials and expanding indications are shaping its market trajectory amid competitive dynamics. Total global sales approached $2 billion in 2022, driven by broadening indications and ongoing research. Future projections estimate a compound annual growth rate (CAGR) of approximately 6-8% over the next five years, supported by clinical advancements, regulatory approvals, and market penetration, especially in emerging markets. This article provides a comprehensive update on clinical development, a detailed market analysis, competitive landscape, and strategic projections, providing crucial insights for stakeholders.

---

What Are the Latest Clinical Trials and Their Implications?

Current Clinical Trials for Xtandi (as of 2023)

Clinical Trial	Phase	Focus Area	Enrollment (Approx.)	Status	Key Objectives	Notable Results or Updates
ENZAMET (NCT02438009)	Phase 3	mCRPC in hormone-sensitive patients	1,125	Completed	Compare enzalutamide vs standard care	Confirmed survival benefit; updated in 2022 with robust overall survival (OS) data
ARCHES (NCT02677896)	Phase 3	Non-metastatic castration-resistant prostate cancer (nmCRPC)	1,150	Completed	Assess metastasis-free survival (MFS)	Enzalutamide extended MFS significantly (HR 0.24, p<0.001)
PROSPER (NCT02003924)	Phase 3	nmCRPC	1,050	Completed	MFS and OS	Showed substantial MFS benefit, approved by FDA in 2018 for nmCRPC
ENZAMET-2 (NCT04524890)	Phase 3	Metastatic hormone-sensitive prostate cancer	Ongoing	Recruitment	Evaluate efficacy with novel combinations	Early data suggest promising activity with combination therapies
ENZANCED (NCT04544521)	Phase 3	Enzalutamide with radiotherapy in localized prostate cancer	Ongoing	Recruitment	Assess efficacy in earlier disease stages	Awaiting interim analysis

Emerging and Investigational Uses

• Combination Therapies: Trials combining enzalutamide with PARP inhibitors (e.g., olaparib), immunotherapies (e.g., pembrolizumab), and radiotherapy are underway to evaluate synergistic effects.
• New Indications: Trials exploring enzalutamide in other cancers such as advanced breast cancer and androgen receptor-positive salivary gland tumors are ongoing.
• Biomarker-driven Approaches: Research is focusing on androgen receptor splice variants as predictors of response, influencing future trial design.

Summary of Clinical Trial Impact

Aspect	Impact & Implications
Expanded Labeling	Approval in nmCRPC, urinating earlier intervention
Combination Strategies	Potential to maintain market dominance while addressing resistance
Biomarker Development	Personalized treatment approaches, improved efficacy
Novel Indications	Growing opportunities in other oncology segments

---

Market Analysis & Dynamics

Market Size and Revenue Trends

Year	Global Sales (USD millions)	CAGR (2018–2022)	Key Growth Drivers
2018	$1,095	—	FDA approval for mCRPC
2019	$1,340	22.2%	Expanded indications, increased adoption
2020	$1,610	20.1%	COVID-19 impact mitigated, clinical trials accelerated
2021	$1,820	13.0%	US/Europe market growth, new approvals
2022	$1,950	7.1%	Market saturation, emerging markets' entry

Market Breakdown by Region (2022)

Region	Market Share	Revenue (USD millions)	Key Drivers
North America	65%	$1,267	Pioneering approvals, high awareness
Europe	20%	$390	Broadening indications, reimbursement
Asia-Pacific	10%	$195	Emerging markets, increasing prostate cancer incidence
Rest of World	5%	$98	Licensing, smaller healthcare spends

Key Market Players

Company	Product Portfolio	Market Share (Estimated)	Notable Strategic Moves
Bayer/Johnson & Johnson	Xtandi	~70%	Focused on expanding indications, lifecycle management
Pfizer	Enzalutamide (original formulation)	Acquired via J&J	Enhancing access in emerging markets
Clovis Oncology	Development of PARP inhibitor combinations	Emerging in pipeline	Strategic partnerships for combination therapies
Other Competitors	Darolutamide, Apalutamide	30% combined	Alternative AR inhibitors with different profiles

Pricing and Reimbursement Landscape

Region	Average Price per Month	Reimbursement Policy Highlights	Challenges
North America	$8,000–$10,000	Widely reimbursed with PBMs	Price pressure, payor restrictions
Europe	€6,000–€8,000	Reimbursement varies by country	Cost containment policies
Asia-Pacific	$2,000–$4,000	Mix of public and private coverage	Pricing regulation, access
Latin America/Africa	<$2,000	Limited coverage	Affordability constraints

---

Market Projections and Future Outlook

Forecast Growth Drivers

• Broadened Indications: FDA approvals for nmCRPC and earlier stages fuel sales.
• Combination Therapies: Clinical success in combination regimens (e.g., PARP inhibitors, immunotherapy) enhances therapeutic value.
• Emerging Markets: Increased healthcare infrastructure and prostate cancer prevalence expand market reach.
• Enhanced Diagnostic Tools: Biomarker-driven approaches facilitate personalized therapy, improving outcomes and market penetration.
• Patent Expiry & Generics: Patents expected to expire by 2027; biosymmetric approval pathways may accelerate generics.

Projected Market Growth (2023–2028)

Year	Estimated Market Size (USD million)	CAGR	Notes
2023	$2,200		Current baseline
2024	$2,400	8%	Slight uptake in emerging markets
2025	$2,600	8.3%	Introduction of new combination therapies
2026	$2,800	7.7%	Approvals of new indications, biosimilars enter
2027	$3,000	7.1%	Patent expiry approaching, generic competition begins
2028	$3,250	8.3%	Market adjustments, new therapy combinations

Strategic Opportunities & Risks

Opportunities	Risks
Expanding into new oncologic indications	Patent expiries leading to biosimilar competition
Developing combination regimens	Regulatory hurdles for novel combinations
Market expansion in Asia and Latin America	Pricing pressure and reimbursement constraints
Incorporation of companion diagnostics	Clinical trial failures delaying pipeline progression

---

Comparison with Competitors

Therapy	Mechanism of Action	Indications	Market Share (2022)	Key Differentiators	Limitations
Xtandi (Enzalutamide)	Androgen receptor inhibitor	mCRPC, nmCRPC, mHSPC	70%	Oral administration, broad approvals	Seizures risk in some patients
Darolutamide	AR antagonist	nmCRPC	15%	Lower seizure risk, favorable side effect profile	Slightly later market entry
Apalutamide	AR inhibitor	nmCRPC, mHSPC	10%	Validated efficacy	Neural side effects in some cases
Enzalutamide + PARP inhibitors	Combination	Prostate cancer with DNA repair mutations	Emerging	Potential for enhanced efficacy	Complex reimbursement landscape

---

Regulatory and Policy Landscape

Region	Recent/Upcoming Regulatory Actions	Impacts
US	FDA approvals for nmCRPC (2018), early indications for combination trials	Supports market growth and access
EU	EMA approvals aligned; reimbursement varies by country	Expanding access but with regional hurdles
Asia-Pacific	Accelerated reviews and local trials	Increased uptake and market presence
Policy Trends	Focus on value-based pricing, patient access programs	Will influence pricing and adoption strategies

---

Key Takeaways

• Clinical Pipeline Status: Multiple Phase 3 trials affirm enzalutamide's efficacy in earlier prostate cancer stages and in combination with other agents, promising to sustain or grow its market dominance.
• Market Trajectory: Estimated to grow at a CAGR of 6-8% over the next five years driven by expanding indications, clinical advancements, and regional market penetration.
• Competitive Landscape: Predominantly held by Bayer and J&J, with generics and biosimilars poised to enter by 2027, pressuring pricing.
• Regulatory & Reimbursement: Ongoing market access expansion depends heavily on favorable regulatory decisions and reimbursement policies, especially in emerging markets.
• Strategic Outlook: Personalized medicine, combination regimens, and emerging indications represent key growth avenues, with patent expiration looming as a critical factor for future dynamics.

---

FAQs

1. What are the latest regulatory approvals for Xtandi?

In 2022, the FDA approved Xtandi for non-metastatic castration-resistant prostate cancer (nmCRPC), expanding its use beyond metastatic settings. The approval was based on robust clinical trial data demonstrating significant metastasis-free survival benefits.

2. How does Xtandi compare to other androgen receptor inhibitors?

Xtandi offers oral administration with proven efficacy across multiple prostate cancer stages. Compared to darolutamide and apalutamide, Xtandi has a longer market presence and broader approval footprint but may have a higher seizure risk profile, which influences patient selection.

3. What are the main competitive threats to Xtandi?

Upcoming biosimilars and generics post-2027 threaten market share. Additionally, innovative therapies such as PARP inhibitors (e.g., olaparib) and immunotherapies may shift treatment paradigms, especially in biomarker-selected populations.

4. What market opportunities exist outside prostate cancer?

Ongoing trials are exploring enzalutamide in advanced breast cancer and other AR-positive tumors, presenting potential secondary markets if clinical efficacy and regulatory approval are achieved.

5. How do regional policies impact Xtandi’s market growth?

In developed markets like North America and Europe, reimbursement remains strong, maintaining sales. In emerging markets, increasing healthcare access and government programs are crucial, though price controls and regulatory delays pose challenges.

---

References

[1] Bayer. "Xtandi (enzalutamide) clinical trial updates." 2023.
[2] FDA. "FDA approves first treatment for non-metastatic castration-resistant prostate cancer." 2018.
[3] IQVIA. "Prostate cancer therapeutics market report." 2022.
[4] European Medicines Agency. "Regulatory decisions on enzalutamide." 2022.
[5] ClinicalTrials.gov. "Ongoing studies involving enzalutamide." Accessed January 2023.

---

In conclusion, Xtandi's clinical pipeline and expanding indications underpin a positive outlook amid competitive pressures. Strategic focus on combination therapies, regional market expansion, and biomarker-driven treatment will be pivotal in maintaining its market leadership through 2028.